Viridian Therapeutics Inc
$ 30.07
0.03%
11 Feb - close price
- Market Cap 2,868,987,000 USD
- Current Price $ 30.07
- High / Low $ 30.46 / 29.25
- Stock P/E N/A
- Book Value 3.82
- EPS -3.03
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.50 %
- 52 Week High 34.29
- 52 Week Low 9.90
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$42.06
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 | 2023-05-09 | 2023-03-08 |
| Reported EPS | -0.34 | -1 | -0.869 | -0.81 | -1.1546 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 | -1.61 | -1.13 |
| Estimated EPS | -0.9532 | -1 | -1.1 | -1.0442 | -1.06 | -0.89 | -1.1 | -1 | -1.27 | -1.29 | -1.02 | -0.73 |
| Surprise | 0.6132 | 0 | 0.231 | 0.2342 | -0.0946 | -0.13 | 0.31 | -0.35 | 0.18 | 0.02 | -0.59 | -0.4 |
| Surprise Percentage | 64.3307% | 0% | 21% | 22.4287% | -8.9245% | -14.6067% | 28.1818% | -35% | 14.1732% | 1.5504% | -57.8431% | -54.7945% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.9 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2026-02-06 00:30:18
This article analyzes Viridian Therapeutics Inc. (VRDN) stock, highlighting a weak near and mid-term sentiment but a strong long-term outlook. It identifies a significant short setup opportunity with an exceptional risk-reward ratio and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis suggests that despite current weak sentiment, VRDN has strong long-term potential, as indicated by multi-timeframe signal analysis.
2026-02-04 11:58:56
Needham analyst Serge Belanger has reiterated a Buy rating for Viridian Therapeutics (VRDN) and maintained a $42.00 price target. This consistent positive outlook reflects confidence in VRDN's market position and growth potential. Other analysts have also provided varying ratings and price targets, contributing to a consensus "Outperform" status, with an average target price of $40.24, implying a 26.13% upside from its current price.
2026-02-03 13:59:04
Wells Fargo & Company raised its price target for Viridian Therapeutics (NASDAQ:VRDN) to $29.00 from $26.00, maintaining an "equal weight" rating, though this implies a potential downside of 12.65% from its previous close. Despite a significant revenue beat in its last earnings report, the company remains unprofitable with a negative net margin. Institutional investors increased their positions in VRDN during Q4, while an insider sold shares.
2026-02-03 11:44:07
Viridian Therapeutics (NASDAQ: VRDN) is a biotechnology company with a market capitalization of $3.17 billion, showing strong growth potential and favorable analyst ratings. The stock is nearing its 52-week high, driven by an impressive revenue growth rate, and analysts project a potential upside of 26.15% with an average target price of $41.88. The company's pipeline includes veligrotug in Phase 3 trials for thyroid eye disease and VRDN-003 for autoimmune diseases, backing the high buy ratings despite current negative EPS.
2026-01-31 14:02:18
Y Intercept Hong Kong Ltd significantly increased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 430.3% in the third quarter, acquiring an additional 52,414 shares to now own 64,594 shares valued at $1.39 million. This move comes as Viridian Therapeutics beat Q3 earnings estimates with an EPS of ($0.34) and substantial revenue growth, though it maintains a negative net margin. Wall Street analysts largely rate the stock a "Moderate Buy" with a consensus price target of $42.43, even as one insider recently sold shares.
2026-01-28 12:33:12
Evercore ISI has increased its price target for Viridian Therapeutics (NASDAQ:VRDN) to $45.00 from $44.00, maintaining an Outperform rating, based on the potential of its subcutaneous TED data expected in Q1 2026. The firm anticipates significant market share capture for Viridian's subQ product in the estimated $2 billion IGF-1R market, projecting potential peak sales of $1.4 billion worldwide and profitability by 2027. This positive outlook is supported by Viridian's strong financial position and other recent favorable analyst ratings and FDA priority review for its veligrotug treatment.
